Treatment Horizons

Treatment Horizons

FDA Approves First Two-Drug Once-Daily Single-Pill HIV Regimen

On November 21, 2017, the U.S. Food and Drug Administration (FDA) approved the first-ever two-drug once-daily single-pill regimen for the maintenance treatment of adults...

CDC Announces: More people with HIV have the virus under control

On July 26, 2017, the Centers for Disease Control and Prevention released new data on the nation’s progress in HIV testing and treatment, showing...

Fast-Tracked or Foiled?

Last month, the Member States of the United Nations adopted the “Political Declaration on HIV and AIDS: On the Fast-Track to Accelerate the Fight...

Developing Doravirine

LifeGuide Running Into Options An NNRTI candidate seeks to keep on track to expand therapies by Chael Needle In this next-generation era of anti-HIV meds, research and development...

Heart Break in Melbourne

LifeGuide Heart Break in Melbourne Cardiovascular disease studies focus on assessment, management & treatment by Jeannie Wraight Cardiovascular disease (CVD) has become a leading cause of illness and...

Revisiting Immunity

NAPWA helps to promote immune-based therapies by Chael Needle At the International AIDS Conference last June, the AIDS Institute and the National Association of People with AIDS...

The Road Ahead

LifeGuide Treatment Horizons The Road Ahead New candidates hold promise for ARV therapy & therapeutic vaccines by Mariel Selbovitz, MPH The 54th Interscience Conference on Antimicrobial Agents and Chemotherapy...

AMBER Study: Phase 3 Symtuza Results

At the 16th European AIDS Conference in Milan, Italy, on October 25, 2017, Janssen Pharmaceutica, NV announced the results of its Phase 3 AMBER...

Host Restrictive Factors

The Deeper End of the Ocean Host restrictive factors create research excitement by Mariel Selbovitz, MPH, and David Miller The doors on viral host restrictive factors (HRFs),...

AGS-004 Immunotherapy

Treatment Horizons by Chael Needle Fully Personalized An immunotherapy candidate stimulates T-cell responses via patient-specific antigens Previous studies have established immunotherapy candidate AGS-004, both as a single...

LATEST POSTS

We Need to Bring Immune-Based HIV Therapies Off of the Sidelines

Dreaming of the Cells We Had We Need to Bring Immune-Based Therapies Off of the Sidelines by Jeannie Wraight For most people living with HIV, antiretrovirals (ARVs)...